ReviewOncotarget2017
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.Journal of clinical pharmacology · 2017Trial
- Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling.Molecules (Basel, Switzerland) · 2023Review
- Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib.Internal medicine (Tokyo, Japan) · 2022Article
- Semi-Mechanistic PK/PD Modeling and Simulation of Irreversible BTK Inhibition to Support Dose Selection of Tirabrutinib in Subjects with RA.Clinical pharmacology and therapeutics · 2022Article
- Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.The Journal of clinical investigation · 2020Article
- Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.Acta pharmacologica Sinica · 2020Article
- Ibrutinib related bleeding complications in elderly patients with B cell malignancies.Journal of thrombosis and thrombolysis · 2019Article
- Overview of Current Targeted Anti-Cancer Drugs for Therapy in Onco-Hematology.Medicina (Kaunas, Lithuania) · 2019Review
- Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.Molecular immunology · 2019Review
- Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.Current oncology (Toronto, Ont.) · 2019Review
- The B cell receptor signaling pathway in mantle cell lymphoma.Oncotarget · 2018Review
- A Small Molecule Inhibitor of Bruton's Tyrosine Kinase Involved in B-Cell Signaling.ACS omega · 2017Article
- Syk inhibitors in clinical development for hematological malignancies.Journal of hematology & oncology · 2017Review
- Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia.Oncotarget · 2017Article
- Diagnosis and treatment of CD20 negative B cell lymphomas.Biomarker research · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Bruton tyrosine kinase (BTK) inhibitor, ibrutinib, has been approved for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. Acquired resistance to ibrutinib due to BTK C481S mutation has been reported. Mutations in PLCγ2 can also mediate resistance to ibrutinib. Untoward effects due to off-target effects are also disadvantages of ibrutinib. More selective and potent BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being investigated. This review summarized the preclinical research and clinical data of ONO/GS-4059.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.